Pituitary sensitizing effect of GnRH antagonists: A mechanism explaining LH escape during IVF?

Human Reproduction

Volumn 25, Issue 6, 2010, Pages 1513-1519

  Banga, F R ^a   Huirne, J A ^a   Korsen, T ^a   Homburg, R ^a   Hompes, P G A ^a   Lambalk, C B ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antagonist; Escape; GnRH; Pituitary response; Rebound

Indexed keywords

ESTRADIOL; FOLLITROPIN; GANIRELIX; GONADORELIN ACETATE; LUTEINIZING HORMONE; PROGESTERONE;

ADENOHYPOPHYSIS; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; HORMONAL REGULATION; HORMONE RESPONSE; HORMONE SENSITIVITY; HUMAN; HUMAN EXPERIMENT; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; NORMAL HUMAN; POSTMENOPAUSE; PROGESTERONE BLOOD LEVEL; PROVOCATION TEST; TREATMENT DURATION;

EID: 77952811530     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deq092     Document Type: Article

References (30)

1. Belchetz PE, Plant TM, Nakay Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 1978;202:631-633.
2. Broekmans FJ, Hompes PG, Lambalk CB, Schoute E, Broeders A, Schoemaker J. Short term pituitary desensitization: effects of different doses of the gonadotrophin-releasing hormone agonist triptorelin. Hum Reprod 1996;11:55-60.
3. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. N Engl J Med 1991;10:93-103.
4. Conn PM, Crowley WF Jr. Gonadotrophin-releasing hormone and its analogs. Annu Rev Med 1994;45:391-405.
5. Crowley WF Jr, Beitins IZ, Vale W, Kliman B, Rivier J, Rivier C, McArthur JW. The biologic activity of a potent analogue of gonadotropin-releasing hormone in normal and hypogonadotropic men. N Engl J Med 1980;302:1052-1057.
6. Dafopoulos K, Kotsovassilis CG, Milingos S, Kallitsaris A, Galazios G, Zintzaras E, Sotiros P, Messinis IE. Changes in pituitary sensitivity to GnRH in estrogen-treated post-menopausal women: evidence that gonadotrophin surge attenuating factor plays a physiological role. Hum Reprod 2004;19:1985-1992.
7. Docke F, Dorner G. The mechanism of the induction of ovulation by oestrogens. J Endocrinol 1965;33:491-499.
8. Dubourdieu S, Charbonnel B, d'Acremont MF, Carreau S, Spitz IM, Bouchard P. Effect of administration of a GnRH antagonist (Nal-Glu) during the periovulatory period: the LH surge requires secretion of gonadotropin-releasing hormone. J Clin Endocrinol Metab 1994;78: 343-347.
9. Engel JB, Ludwig M, Junge K, Howles CM, Diedrich K. No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single-and multiple-dose protocols. Reprod Biomed Online 2003;6:482-487.
10. Ganirelix dose-finding study group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 1998;13:3023-3031.
11. Gordon K, Scott RT, Williams RF, Danforth DR, Loozen HJ, Kloosterboer HJ, Hodgen GD. In vivo effects of a potent GnRH antagonist ORG 30850: physiologic evidence that down-regulation of GnRH receptors does not occur. J Soc Gynecol Investig 1994;1:290-296.
12. Hall JE. Neuroendocrine changes with reproductive aging in women. Semin Reprod Med 2007;25:344-351.
13. Huirne JA, Lambalk CB. GnRH antagonists. Lancet 2001;358: 1793-1803.
14. Huirne JA, van Loenen AC, Schats R, McDonnell J, Hompes PG, Schoemaker J, Homburg R, Lambalk CB. Dose-finding study of daily gonadotropin-releasing hormone (GnRH) antagonist for the prevention of premature luteinizing hormone surges in IVF/ICSI patients: antide and hormone levels. Hum Reprod 2004;19:2206-2215.
15. Knobil E. The neuroendocrine control of ovulation. Hum Reprod 1988; 3:469-472.
16. Lambalk CB, van Dieten HA, de Koning J, Schoemaker J, van Rees GP. Short-term pituitary desensitization to LH-RH after pulsatile LH-RH in the ovariectomized rat: an in vivo experiment. Neuroendocrinology 1986;43:646-650.
17. Lambalk CB, Schoemaker J, van Rees G, Van Kessel H, de Koning J, van Dieten HA, de Vries Robles-Korsen TJ. Short-term pituitary desensitization to luteinizing hormone-releasing hormone (LH-RH) after pulsatile LH-RH administration in women with amenorrhea of suprapituitary origin. Fertil Steril 1987a;47:385-390.
18. Lambalk CB, van Dieten JA, de Koning J, Schoemaker J, van Rees GP. Phenobarbital enhances pituitary LH release induced by LRH pulses in the ovariectomized rat. Acta Endocrinol (Copenh) 1987b; 114:214-217.
19. Lambalk CB, Schoemaker J, van Rees GP, de Koning J, van Dieten HAMJ. Exogenous versus endogenous pulses of luteinizing hormone-releasing hormone and secretory patterns of gonadotropins. Fertil Steril 1991; 56:446-452.
20. Lambalk CB, de Boer L, Schoute E, Popp-Snyders C, Schoemaker J. Post-menopausal and chronological age have divergent effects on pituitary and hypothalamic function in episodic gonadotrophin secretion. Clin Endocrinol (Oxf) 1997;46:439-443.
21. Leal JA, Gordon K, Williams RF, Danforth DR, Roh SI, Hodgen GD. Probing studies on multiple dose effects of antide (Nal-Lys) GnRH antagonist in ovariectomized monkeys. Contraception 1989; 40:623-633.
22. Marshall LA, Fluker MR, Jaffe RB, Monroe SE. Inhibition of follicular development by a potent antagonistic analog of gonadotropin-releasing hormone (detirelix). J Clin Endocrinol Metab 1991;72:927-933.
23. Moenter SM, Caraty A, Karsch FJ. The estradiol-induced surge of gonadotropinreleasing hormone in the ewe. Endocrinology 1990; 127:1375-1384.
24. Moenter SM, Chu Z, Christian CA. Neurobiological mechanisms underlying oestradiol negative and positive feedback regulation of gonadotropin-releasing hormone (GnRH) neurones. J Neuroendocrinol 2009;21:327-333.
25. Nelson LR, Fujimoto VY, Jaffe RB, Monroe SE. Suppression of follicular phase pituitary gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix). Fertil Steril 1995;63:963-969.
26. Oberyé JJ, Mannaerts BM, Huisman JA, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril 1999a; 72:1001-1005.
27. Oberyé JJ, Mannaerts BM, Huisman JA, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil Steril 1999b; 72:1006-1012.
28. ′-monophosphate (mbcAMP) plus theophylline. Acta Endocrinol (Copenh) 1985;108: 331-337.
29. van Rees GP, van Dieten JA, de Koning J, de Goey AF. Effect of pre-treatment of long-term ovariectomized rats with anti-LRH on the response of the pituitary gland in vitro to the analogue of LRH D-ser-(tBu)6-des-gly10- ethylamide-LRH (Buserelin). Acta Endocrinol (Copenh) 1983;104: 272-278.
30. Weiss J, Cote CR, Jameson JL, Crowley WF Jr. Homologous desensitization of gonadotropin-releasing hormone (GnRH)-stimulated luteinizing hormone secretion in vitro occurs within the duration of an endogenous GnRH pulse. Endocrinology 1995; 136:138-143.